Home » Stocks » APLS

Apellis Pharmaceuticals, Inc. (APLS)

Stock Price: $67.86 USD 0.16 (0.24%)
Updated Jul 29, 2021 12:18 PM EDT - Market open
Market Cap 5.45B
Revenue (ttm) 250.65M
Net Income (ttm) -359.71M
Shares Out 79.22M
EPS (ttm) -4.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $67.86
Previous Close $67.70
Change ($) 0.16
Change (%) 0.24%
Day's Open 67.83
Day's Range 66.29 - 69.62
Day's Volume 249,842
52-Week Range 25.49 - 73.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 hours ago - Zacks Investment Research

WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its ...

3 days ago - GlobeNewsWire

WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered...

3 weeks ago - GlobeNewsWire

WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company a...

3 weeks ago - GlobeNewsWire

Apellis (APLS) signs a collaboration deal with Beam Therapeutics to develop new treatments for complement-driven diseases. Shares rise.

3 weeks ago - Zacks Investment Research

Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven diseases. The partnership will leverage Beam...

4 weeks ago - Benzinga

Collaboration combines Apellis' expertise in complement, a complex biological system, with Beam's proprietary base editing platform

4 weeks ago - GlobeNewsWire

Investors seem to think that a drug from fledgling biotech Apellis Pharmaceuticals ( APLS , Financial) can go head-to-head with established treatments backed by a competitor 10 times its size.

Other stocks mentioned: ALXN
1 month ago - GuruFocus

The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive outcomes.

Other stocks mentioned: BBIO, JNJ, LNTH
1 month ago - Benzinga

Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.

2 months ago - Zacks Investment Research

Apellis Pharmaceuticals Inc (NASDAQ: APLS) and Swedish Orphan Biovitrum AB (SOBI) have reported positive top-line results from the Phase 3 PRINCE study evaluating Empaveli (pegcetacoplan) in treatment n...

2 months ago - Benzinga

STOCKHOLM, May 25, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (GLOBE NEWSWIRE) today reported positive top-line results from the pha...

2 months ago - PRNewsWire

With the trading day more than halfway over, the markets were somewhat mixed going into the weekend.

Other stocks mentioned: BLMN, FOLD, STX, ONEM, PLCE, SBRA
2 months ago - 24/7 Wall Street

Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.

2 months ago - Zacks Investment Research

Investors need to pay close attention to Apellis (APLS) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

The FDA approves Apeliis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients.

2 months ago - Zacks Investment Research

The FDA has approved Apellis Pharmaceuticals Inc's (NASDAQ: APLS) Empaveli (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare blood disease that ca...

2 months ago - Benzinga

WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S. Food ...

2 months ago - GlobeNewsWire

WALTHAM, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that seven abstrac...

2 months ago - GlobeNewsWire

WALTHAM, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ap...

2 months ago - GlobeNewsWire

Apellis' (APLS) earnings lag estimates in the first quarter of 2021. Main focus of the company is on its lead pipeline candidate, pegcetacoplan.

3 months ago - Zacks Investment Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -37.28% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for th...

3 months ago - Zacks Investment Research

WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its first quarter...

3 months ago - GlobeNewsWire

Apellis Pharmaceuticals, Inc. (APLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

NEW YORK, April 26, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty c...

3 months ago - PRNewsWire

WALTHAM, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company...

3 months ago - GlobeNewsWire

WALTHAM, Mass., April 16, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that 10 abstract...

3 months ago - GlobeNewsWire

With the trading day about halfway over, the broad markets were trading sideways into the weekend, despite the Dow Jones industrials and the S&P 500 setting record intraday highs in the session.

Other stocks mentioned: AMZN, CMG, DIS, ARRY, BE, JKS
3 months ago - 24/7 Wall Street

WALTHAM, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced 24-month data fro...

3 months ago - GlobeNewsWire

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

WALTHAM, Mass. and STOCKHOLM, March 17, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the New Engla...

4 months ago - GlobeNewsWire

WALTHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) --   Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that two leadi...

4 months ago - GlobeNewsWire

WALTHAM, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ...

4 months ago - GlobeNewsWire

Following an interim review of mortality data by an independent data monitoring committee (DMC), Apellis Pharmaceuticals Inc (NASDAQ: APLS) will not pursue additional development of APL-9 for the treatm...

4 months ago - Benzinga

WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ...

4 months ago - GlobeNewsWire

Apellis' (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Main focus of the company is on lead pipeline candidate, pegcetacoplan.

5 months ago - Zacks Investment Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of 293.75% and 35.47%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for t...

5 months ago - Zacks Investment Research

WALTHAM, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ...

5 months ago - GlobeNewsWire

WALTHAM, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company a...

5 months ago - GlobeNewsWire

WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its ...

6 months ago - GlobeNewsWire

WALTHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company w...

6 months ago - GlobeNewsWire

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered...

6 months ago - GlobeNewsWire

Apellis' (APLS) lead pipeline candidate, pegcetacoplan, is a promising one and being developed for several indications.

7 months ago - Zacks Investment Research

STOCKHOLM and WALTHAM, Mass., Dec. 10, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals Inc. (Nasdaq: APLS) today announced positive top-line result...

7 months ago - PRNewsWire

WALTHAM, Mass. and STOCKHOLM, Sweden, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi™ Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced posit...

7 months ago - GlobeNewsWire

WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company a...

7 months ago - GlobeNewsWire

WALTHAM, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company ...

7 months ago - GlobeNewsWire

Apellis (APLS) and Sobi dose the first patient in the mid-stage MERIDIAN study, which is investigating pegcetacoplan to address adults with sporadic amyotrophic lateral sclerosis.

8 months ago - Zacks Investment Research

STOCKHOLM and WALTHAM, Mass., Nov. 19, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (SobiTM) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the first patient...

8 months ago - PRNewsWire

WALTHAM, Mass. and STOCKHOLM, Sweden, Nov. 19, 2020 (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the f...

8 months ago - GlobeNewsWire

About APLS

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous n... [Read more...]

Industry
Biotechnology
IPO Date
Nov 9, 2017
CEO
Cedric Francois
Employees
391
Stock Exchange
NASDAQ
Ticker Symbol
APLS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for APLS stock is "Buy." The 12-month stock price forecast is 79.47, which is an increase of 17.11% from the latest price.

Price Target
$79.47
(17.11% upside)
Analyst Consensus: Buy